(Q46758156)

English

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

scientific article published on 6 October 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

1 reference

based on heuristic

inferred from title

author name string

Luis E Jauregui

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Simon Babazadeh

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Elyse Seltzer

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Lisa Goldberg

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Dainis Krievins

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Mark Frederick

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

David Krause

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Igors Satilovs

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Zilvinas Endzinas

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Jeffrey Breaux

10

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

William O'Riordan

11

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

language of work or name

0 references

publication date

6 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

41

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

10

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

1407-1415

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Linezolid: a review of its use in the management of serious gram-positive infections

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

The changing epidemiology of Staphylococcus aureus?

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Methicillin-resistant Staphylococcus aureus: impact on dermatology practice

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Community-acquired methicillin-resistant Staphylococcus aureus among military recruits

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Maximizing efficacy and reducing the emergence of resistance

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

1 reference

https://api.crossref.org/works/10.1086%2F497271

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16231250

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46758156&oldid=2129978572"